Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: voltage-gated potassium channels - Correvio Pharma

Drug Profile

Research programme: voltage-gated potassium channels - Correvio Pharma

Alternative Names: Kv 1.5 channel blockers - Cardiome; Voltage-gated potassium channels research programme - Correvio Pharma

Latest Information Update: 21 May 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cardiome Pharma
  • Class
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Arrhythmias

Most Recent Events

  • 15 May 2018 Cardiome Pharma is now called Correvio Pharma
  • 14 Sep 2004 Discontinued - Preclinical for Arrhythmias in Canada (unspecified route)
  • 26 Sep 2001 This programme is available for licensing (www.cardiome.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top